Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.

Purpose:Giant cell tumor of bone (GCTB) is a local aggressive bone tumor, histologically classified as intermediate malignancy. Recently, the RANKL inhibitor, denosumab, was developed as a novel an...